Epub 2020 Apr 30.Fortuna GMG, Rios P, Rivero A, Zuniga G, Dvir K, Pagacz MM, Manzano A.J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620942672. doi: 10.1177/2324709620942672. As a function of their risk associations, each category is linked to updated, evidence-based clinical management recommendations. The 2017 Bethesda System for Reporting Thyroid Cytopathology Edmund S. Cibas1 and Syed Z. Ali2 The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. Such notes can be useful in helping guide surgical management.TBSRTC has been widely adopted in the United States and in many places worldwide and has been endorsed by the American Thyroid Association (The symposium, moderated by Drs. Unable to load your delegates due to an error An inspiration for the thyroid proposal was the Bethesda System for reporting cervical cytology inter-pretations, first developed at an NCI workshop in 1988 and The 2017 revision reaffirms that every thyroid FNA report should begin with one of six diagnostic categories, the names of which remain unchanged since they were first introduced: (i) nondiagnostic or unsatisfactory; (ii) benign; (iii) atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS); (iv) follicular neoplasm or suspicious for a follicular neoplasm; (v) suspicious for malignancy; and (vi) malignant. May 2018—Surgical pathologists take their tumor nomenclature from the WHO Classification of Tumours, but cytopathologists take their terminology from where the consensus groups convened—Bethesda, Paris, Milan, and Yokohama—to formulate terminology recommendations. (vii) An optional education note may be used for “malignant; papillary thyroid carcinoma” cases to acknowledge that a small proportion may prove to be NIFTP.It is our hope that the 2017 BSRTC will continue to stimulate interest in the improvement of thyroid cytopathologic diagnosis and the betterment of patients with thyroid nodular disease. To avoid false-positives due to NIFTP, it suggests limiting use of the malignant category to cases with “classical” features of papillary thyroid carcinoma (true papillae, psammoma bodies, and nuclear pseudoinclusions) (Note: A small proportion of cases (∼3–4%) diagnosed as malignant and compatible with papillary thyroid carcinoma may prove to be NIFTP on histopathologic examination.The original six categories remain unchanged, but a number of enhancements have been introduced with the 2017 BSRTC: (i) The risks of malignancy have been recalculated based on the post-2010 data. For this subset, the following optional note (or something similar) may be useful (Note: The cytomorphologic features are suspicious for a follicular variant of papillary thyroid carcinoma or its recently described indolent counterpart NIFTP.This can be useful in guiding the clinical team in the direction of lobectomy rather than thyroidectomy for this subset of SUS cases.The general category “malignant” is used whenever the cytomorphologic features are conclusive for malignancy. This can happen when a cyst is aspirated or when the specimen is almost entirely composed of blood. Bethesda Classification of Thyroid Nodule Fine Needle Aspirations I. Nondiagnostic or Unsatisfactory. ology, published in 2010, in English, is linked with a percentage of risk cancer for each of its diagnostic category and with a suitable treatment. Enter your email address below and we will send you the reset instructionsIf the address matches an existing account you will receive an email with instructions to reset your password.Enter your email address below and we will send you your usernameIf the address matches an existing account you will receive an email with instructions to retrieve your usernameDepartments of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland.The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. Lowering the required number of follicular cells would save many patients a repeat FNA. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. Institutional Login 2017 Nov-Dec;6(6):217-222. doi: 10.1016/j.jasc.2017.09.002. The recent reclassification of some thyroid neoplasms as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has implications for the risk of malignancy, and this is accounted for with regard to diagnostic criteria and optional notes. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC)1 is now in its second edition. Some laboratories, for example, may wish to state the risk of malignancy (ROM) associated with the general category, based on its own data or those found in the literature.Every thyroid FNA should be evaluated for specimen adequacy. The 2017 revision reaffirms that every thyroid FNA report should begin with one of six diagnostic categories, the names of … Epub 2017 Nov 30.Lau RP, Paulsen JD, Brandler TC, Liu CZ, Simsir A, Zhou F.Am J Clin Pathol. By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. Each category has an implied cancer risk that ranges from 0% to 3% for the “Benign” category to virtually 100% for the “Malignant” category, and, in the 2017 revision, the malignancy risks have been updated based on new (post 2010) data. 114 September 2018 | Clinical Thyroidology, Vol. Descriptive comments that follow are used to subclassify the malignancy and summarize the results of special studies, if any.Based on early studies, NIFTP constitutes only a very small fraction of cases that are interpreted as “malignant.” Nevertheless, the 2017 BSRTC has modified the definition and criteria for cases of papillary thyroid carcinoma that belong in the malignant category. 2017 Dec 20;149(1):50-54. doi: 10.1093/ajcp/aqx136.Adv Anat Pathol. Published by Elsevier Inc. All rights reserved.ScienceDirect ® is a registered trademark of Elsevier B.V. As a function of their risk associations, each category is linked to updated, evidence-based clinical management recommendations. 2020 Jul;54(4):318-331. doi: 10.4132/jptm.2020.02.26. due to its less provoking nature, as follows: It is good to think of AUS/FLUS as a category of last resort.